Loading
PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Talazoparib and Carfilzomib. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.78, genetic association 0.12, clinical 0.99).
In plain words · PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.
PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
No product in this corpus aims at PSMD4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists PSMD4 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMD4: RNA low tissue specificity; high antibody staining in 6 normal tissues. Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Colorectal cancer, Breast cancer (all types), Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PSMD4 tissue; Open Targets ENSG00000159352 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Johansson et al, J. Biol. Chem, 1995, "Molecular cloning and expression of a pituitary gland protein modulating intestinal fluid secretion". Source.
Sources: HGNC HGNC:9561 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P55036 (protein name, function text, keywords and locations (REST API)); CIViC gene PSMD4 (2 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Breast Cancer (GraphQL API, CC0)); Open Targets ENSG00000159352 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMD4 acts as an ubiquitin receptor subunit through ubiquitin-interacting motifs and selects ubiquitin-conjugates for destruction. Displays a preferred selectivity for longer polyubiquitin chains. Locus 1q21.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Bone marrow, Bronchus, Cervix, Duodenum, Endometrium, Epididymis.
No cancer stained high; medium in breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA PSMD4 tissue · HPA PSMD4 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PSMD4" OR ABSTRACT:"PSMD4" OR TITLE:"proteasome 26S subunit ubiquitin receptor, non-ATPase 4" OR ABSTRACT:"proteasome 26S subunit ubiquitin receptor, non-ATPase 4" OR TITLE:"26S proteasome non-ATPase regulatory subunit 4" OR ABSTRACT:"26S proteasome non-ATPase regulatory subunit 4" OR TITLE:"S5A" OR ABSTRACT:"S5A" OR TITLE:"AF-1" OR ABSTRACT:"AF-1" OR TITLE:"Rpn10" OR ABSTRACT:"Rpn10") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMD4, not a curated reading list.